UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• UBS Asset Management increased its IDEXX Laboratories stake by 4.6% in the second quarter, adding 39,700 shares to reach 911,489 shares valued at approximately $479.8 million. Institutional investors collectively own 87.84% of the company.
• Analyst sentiment remains positive but mixed: IDEXX has a consensus “Moderate Buy” rating and an average price target of $747, while several firms recently raised targets and others downgraded or lowered their outlooks.
• IDEXX exceeded quarterly expectations with $4.27 in earnings per share and $1.22 billion in revenue, up 9.7% year over year. Shares opened at $554.99, near the lower end of their 12-month range of $518.55 to $769.98.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 911,489 shares of the company's stock after purchasing an additional 39,700 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.16% of IDEXX Laboratories worth $479,844,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of IDXX. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $25,000. SHP Wealth Management purchased a new position in IDEXX Laboratories during the fourth quarter worth $26,000. Elevation Wealth Partners LLC raised its holdings in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after acquiring an additional 32 shares during the last quarter. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at $26,000. Finally, WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at $30,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on IDXX shares. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. UBS Group lifted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Barclays cut their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Weiss Ratings downgraded shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $747.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $554.99 on Monday. The business's 50-day moving average price is $559.01 and its 200 day moving average price is $573.33. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The company has a market capitalization of $43.72 billion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 2.96 and a beta of 1.54. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source